These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22402063)

  • 1. Renin as a biomarker of cardiovascular disease in clinical practice.
    Volpe M; Battistoni A; Chin D; Rubattu S; Tocci G
    Nutr Metab Cardiovasc Dis; 2012 Apr; 22(4):312-7. PubMed ID: 22402063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Activation of the renin-angiotensin-aldosterone system in heart failure].
    Volpe M; Tocci G; Pagannone E
    Ital Heart J; 2005 May; 6 Suppl 1():16S-23S. PubMed ID: 15945296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma renin and cardiovascular risk: what is the evidence for an association?
    Volpe M; Unger T
    Cardiology; 2013; 125(1):50-9. PubMed ID: 23636010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Link between the renin-angiotensin system and insulin resistance: implications for cardiovascular disease.
    Zhou MS; Schulman IH; Zeng Q
    Vasc Med; 2012 Oct; 17(5):330-41. PubMed ID: 22814999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?
    Volpe M
    QJM; 2012 Jan; 105(1):11-27. PubMed ID: 22011630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin-angiotensin-aldosterone system blockade in diabetes: role of direct renin inhibitors.
    Estacio RO
    Postgrad Med; 2009 May; 121(3):33-44. PubMed ID: 19491538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of plasma renin activity in heart failure.
    Vergaro G; Emdin M; Iervasi A; Zyw L; Gabutti A; Poletti R; Mammini C; Giannoni A; Fontana M; Passino C
    Am J Cardiol; 2011 Jul; 108(2):246-51. PubMed ID: 21545993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction.
    Sciarretta S; Paneni F; Palano F; Chin D; Tocci G; Rubattu S; Volpe M
    Clin Sci (Lond); 2009 Mar; 116(6):467-77. PubMed ID: 19200056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention.
    Vijayaraghavan K; Deedwania P
    Cardiol Clin; 2011 Feb; 29(1):137-56. PubMed ID: 21257105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin-angiotensin-aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke).
    Laragh JH
    J Hum Hypertens; 1995 Jun; 9(6):385-90. PubMed ID: 7473515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Possibilities of laboratory diagnosis in the assessment of the activity of the renin-angiotensin-aldosterone system].
    Maksimov ML
    Ter Arkh; 2010; 82(6):77-80, inside back cover. PubMed ID: 20731118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension.
    Morishita Y; Hanawa S; Chinda J; Iimura O; Tsunematsu S; Kusano E
    Hypertens Res; 2011 Mar; 34(3):308-13. PubMed ID: 21124333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review.
    Duprez DA
    J Hypertens; 2006 Jun; 24(6):983-91. PubMed ID: 16685192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring and targeting aldosterone and renin in atherosclerosis-a review of clinical data.
    Hillaert MA; Lentjes EG; Beygui F; Kemperman H; Asselbergs FW; Nathoe HM; Agostoni P; Voskuil M; Ivanes F; Jude B; Bertrand ME; Pasterkamp G; van der Graaf Y; Doevendans PA; Montalescot G; Van Belle E
    Am Heart J; 2011 Oct; 162(4):585-96. PubMed ID: 21982648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aliskiren in the treatment of hypertension and organ damage.
    Riccioni G
    Cardiovasc Ther; 2011 Feb; 29(1):77-87. PubMed ID: 21106033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.